Walleye Capital LLC Makes New $8.93 Million Investment in Inhibrx, Inc. (NASDAQ:INBX)

Walleye Capital LLC purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 579,999 shares of the company’s stock, valued at approximately $8,932,000.

Several other hedge funds also recently modified their holdings of the business. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Inhibrx during the 4th quarter valued at $348,000. Exchange Traded Concepts LLC bought a new position in shares of Inhibrx during the 4th quarter worth about $148,000. Bank of New York Mellon Corp acquired a new position in shares of Inhibrx during the fourth quarter valued at about $792,000. Meridian Wealth Advisors LLC bought a new stake in shares of Inhibrx in the fourth quarter valued at about $385,000. Finally, Arbiter Partners Capital Management LLC acquired a new stake in Inhibrx during the fourth quarter worth about $433,000. 82.46% of the stock is owned by institutional investors.

Inhibrx Stock Down 0.8 %

Shares of INBX stock opened at $11.79 on Wednesday. The stock has a fifty day moving average price of $13.20 and a 200 day moving average price of $14.26. Inhibrx, Inc. has a one year low of $10.80 and a one year high of $34.90.

Inhibrx (NASDAQ:INBX) last posted its earnings results on Monday, March 17th. The company reported ($3.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.88) by ($0.21). The company had revenue of $0.10 million for the quarter. On average, research analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.